Abstract Purpose of Review Stroke is a leading cause of death and disability worldwide. The
annual incidence of new or recurrent stroke is approximately 795,000 cases per year in the …

Prothrombin complex concentrates (PCCs) contain vitamin K-dependent clotting factors (II,
VII, IX, and X) and are marketed as 3 or 4 factor-PCC formulations depending on the …

Background Severe trauma continues to represent a global public health issue and mortality
and morbidity in trauma patients remains substantial. A number of initiatives have aimed to …

1.1. Necessidade de atualização Atualmente, existe uma enorme quantidade de
evidências científicas sobre um determinado assunto, com o objetivo de auxiliar os …

Ischemic stroke represents one of the leading causes of death and disability in both the
United States and abroad, particularly for patients with prior ischemic stroke or transient …

Coagulation tests range from global or overall tests to assays specific to individual clotting
factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant …

Abstract Direct factor Xa (FXa) inhibitors lack a specific reversal agent for emergencies such
as major bleeding or urgent surgery. Andexanet alfa, a modified, catalytically inactive …

Andexanet alfa is a specific reversal agent for Factor Xa inhibitors. The molecule is a
recombinant protein analog of factor Xa that binds to Factor Xa inhibitors and antithrombin …

Essentials• Prothrombin complex concentrates (PCCs) may reverse the effect of factor Xa
(FXa) inhibitors.• We conducted an open‐label, randomized, placebo‐controlled, three …

Background The management of life-threatening bleeding in patients who are receiving
direct oral anticoagulants (DOACs) is a serious medical concern. Objective This review …